Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study

Turkish Journal of Cancer

Volumn 34, Issue 1, 2004, Pages 19-23

  Özdoǧan, Mustafa ^a   Samur, Mustafa ^a   Bozcuk, Hakan ^a   Çoban, Erkan ^a   Artaç, Mehmet ^a   Savaş, Burhan ^a  

^a AKDENIZ UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

Non small cell lung cancer; Survival; Third line chemotherapy

Indexed keywords

CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE; PACLITAXEL;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COHORT ANALYSIS; EVALUATION; HUMAN; LUNG NON SMALL CELL CANCER; PERFORMANCE; PREDICTION; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

EID: 33646266480     PISSN: 10193103     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Parker SL, Tong T, Bolden et al. Cancer statistics, 1996. CA Cancer J Clin 1997;47:5-27.
2. th ed. Philadelphia: J.B. Lippincott Co., 2001;925-51.
3. Shepherd FA. Second-line chemotherapy for non-small cell lung cancer: is more better or just simply more? Lung Cancer 2002;36:309-11.
4. Lynch T. Review of two phase III randomized trials of single-agent docetaxel in previously treated advanced non-small cell lung cancer. Semin Oncol 2001;28:5-9.
5. Kris MG. What does chemotherapy have to offer patients with advanced-stage non-small cell lung cancer? Semin Oncol 1998;25:1-4.
6. Shepherd F, Dancey J, Ramlau R, et al. A prospective randomized trial of docetaxel (Taxotere) versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-103.
7. Fosella VF, Lynch T, Shepherd AF. Second line chemotherapy for NSCLC: establishing a gold standard. Lung Cancer 2002;38:45-50.
8. Fukuoka M, Yano S, Giaccone G, et al. Final results from phase II trial of ZD 1839 (Iressa) for patients with advanced non-small cell lung cancer (IDEAL 1). Proc Am Soc Clin Oncol 2002;22:abstr 1188.
9. Kris M, Natale R, Herbst R, et al. A phase II trial of ZD 1839 (Iressa) in advanced non-small cell lung cancer patients who had failed platinum and docetaxel-based regimens (IDEAL 2). Proc Am Soc Clin Oncol 2002;21:abstr 1166.
10. Georgoulias VA. Second-line chemotherapy in relapsing or refractory patients with non-small cell lung cancer. Lung Cancer 2002;38:3:61-6.
11. Massarelli E, Andre F, Liu DD, et al. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer 2003;39:55-61.